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INTRODUCTION and PURPOSE
• In the most recent American Society for Apheresis Guidelines on the Use of
Therapeutic Apheresis in Clinical Practice, employing therapeutic plasma
exchange (TPE) for long-term treatment of myasthenia gravis (MG) patients
– New indication
– Category II, grade 2B recommendation.

• Data for this indication is evolving
• Subjective assessments of these patients are often uninformative,.
• We sought to better characterize the impacts of long-term TPE in these MG
patients using validated instruments.

METHODS
In this prospective observational study, we used a combination of validated
instruments and open-ended questions clarifying concerns that are routinely applied
to MG patients. The two validated instruments were the MG Activities of Daily
Living (MG-ADL) and MG Quality of Life 15 (MG-QoL15r) profiles. Based on
previous literature, a 2-point change in the MG-ADL and a 10-point change in the
MG-QoL15r indicates significant improvement or worsening. Over a 3-month period,
MG patients receiving long-term TPE were assessed using a single-form
questionnaire that integrated all of the MG-ADL and MG-QoL15r elements and was
completed at every visit. Patients unable to complete the survey due to their medical
condition were exempted.

QUESTIONAIRE

RESULTS
Demographic

Number (%)

Total number of patients

9 (100%)

Total number of treatments

58

Female Patients

5 (56%)

White, non-Hispanic

6 (67%)

Median age

54

Frequency of treatments

3/week to 1/month

Clinically stable patients

5

Most Bothersome Symptom

Time Interval Between
Treatments

Breathing/
chest pain
46%

Don't
know/not
sure
18%
Too short
(need fewer
treatments)
3%
Too long
(need less
time in
between
treatments)
9%

Large
muscle
weakness
31%

Double
vision
3%

Fatigue
6%

Chewing
3%

Just right
70%

Talking
5%
Choking/
swallowing
6%

• Active pharmacotherapy included prednisone, azathioprine, mycophenolate, rituximab, and pyridostigmine.
• All patients reported that lengthening the interval between successive TPE treatments, even by a few days,
resulted in noticeable MG changes.
• During the study period, 4 patients (44%) had significant changes identified by the MG-ADL, a mean of 5.5 times
per patient (range 2-8) and 2 (22%) had significant changes identified by the MG-QoL15r, a mean of 2 times per
patient (range 1-3).
• MG-ADL appeared to be more sensitive in correlating with patient-reported clinical changes, with clinical
improvements identified a mean of 3.2 times per patient and clinical deteriorations identified a mean of 2.3 times
per patient (compared to 1.5 and 1 times per patient, respectively, for the MG-QoL15r; p=0.03 for interaction
effect).
• Subjective clinical deteriorations were correlated with objectively worsening MG-ADL scores, and was
used as evidence to medically justify intensification of TPE therapy.

CONCLUSIONS
• Objective longitudinal assessments in MG patients receiving long-term TPE may be helpful for accurate disease
monitoring.
• A subset of MG patients receiving long-term TPE still has dynamic changes in disease status as assessed by clinical
history and two different validated instruments.
• In all patients with stable MG, both the MD-ADL and MG-QoL15r accurately indicated no significant changes.
• In patients with fluctuating disease status, MG-ADL was more sensitive to both clinical improvement and worsening.
• These findings need to be validated in larger studies.

